Abstract 1865P
Background
This study aimed to determine how the chemotherapy process can lead to a change in self-esteem in elderly patients with early-stage breast cancer according to personality type.
Methods
The research was completed as a pilot study between 2019-2022. Female patients aged 65 and over who were planned for adjuvant treatment were included in the study. Personality type and self-esteem were determined in all patients before and after adjuvant chemotherapy. Bortner Rating Scale was used to determine personality type, and Rosenberg Self-Esteem Scale was used to determine self-confidence. Paired t-test was performed for recurrent variables in pre-treatment and post-treatment measures. Multivariate logistic (binary) regression analysis was performed to determine the independent factors affecting low self-esteem from the study variables with the model created as a result of correlation and univariate analysis. Statistical analysis was performed using the SPSS v19 program and a p value of <0.05 was considered statistically significant.
Results
A total of 69 Her2-negative elderly female patients were included in this pilot study. The mean age of the patients was 68 years (65-72). 54% had radical mastectomy. 69% received paclitaxel for 12 weeks, 21% received 6x DC, and 10% received 3x CEF followed by 3x docetaxel for adjuvant setting. 56% of them had personality type A. Before treatment, 62% had high self-esteem and this was significantly higher in type A personality than in type B (84% vs 48%, respectively; p=0.037). While the rate of high self-esteem decreased in type A personality after treatment (p=0.009), there was no change in type B personality (p=0.379). It was determined that type A personality structure was independent affecting low self-esteem after treatment (OR 5.37 95%CI 1.489-9.396; p=0.006).
Conclusions
In this study, it was concluded that elderly women with type A personality structure may be more sensitive and may have low self-esteem after the treatment is completed. It was concluded that the personality type should be guided by the patient's treatment compliance, need for psychosocial support, and coping methods after the completion of the treatment, supported by the physician.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
Ethics committee approval could not be obtained because it was a pilot study. In the follow-up research, the results of the pilot study will be declared and consent will be obtained.
Funding
Has not received any funding.
Disclosure
The author has declared no conflicts of interest.
Resources from the same session
1999P - IMreal Cohort 4: Third interim analysis of efficacy and safety in patients (pts) with extensive-stage small cell lung cancer (ES-SCLC) receiving atezolizumab plus carboplatin and etoposide (atezo + CE) as first-line (1L) therapy under real-world conditions (RWCs)
Presenter: Sanjay Popat
Session: Poster session 05
2000P - Efficacy and safety of thoracic radiotherapy after first-line immunotherapy in extensive stage small cell lung cancer: A multi-center retrospective study
Presenter: Jiake Wu
Session: Poster session 05
2001P - Consolidative thoracic radiotherapy of extensive-stage small cell lung cancer in the era of chemoimmunotherapy: A retrospective analysis concerning patients from southern Italy
Presenter: Vito Longo
Session: Poster session 05
2002P - A multicentre study assessing the real-world effectiveness of first-line chemotherapy plus immunotherapy in extensive-stage small cell lung cancer (ES-SCLC) patients
Presenter: Marie Porte
Session: Poster session 05
2003P - Consolidative intrathoracic radiotherapy during maintenance first-line immunotherapy in extensive stage small cell lung cancer (ES-SCLC): A retrospective multicenter analysis of safety and efficacy
Presenter: Alessio Bruni
Session: Poster session 05
2004P - PD-L1 Inhibitors combined with whole brain radiotherapy in patients with small cell lung cancer brain metastases: Real-world evidence
Presenter: Litang Huang
Session: Poster session 05
2005P - Anlotinib combined with chemotherapy in the treatment of first-line extensive-stage small cell lung cancer (ES-SCLC): A real-world study
Presenter: Fangfang Gao
Session: Poster session 05
2006P - Immune activation effect and survival of different irradiated sites in ES-SCLC patients treated with radioimmunotherapy: A real-world analysis
Presenter: Min Wu
Session: Poster session 05
2007P - Real-world (rw) outcomes to chemoimmunotherapy and biomarker analysis in extensive-stage small cell lung cancer (ES SCLC)
Presenter: Emmanouil Panagiotou
Session: Poster session 05